Focal gets FDA panel date for May:
This article was originally published in Clinica
The US FDA's advisory panel will review Focal's premarket approval application for its surgical sealant for stemming air leaks on May 8. The Lexington, Massachusetts-based company's FocalSeal-L was accepted for expedited review in June 1999 (see Clinica No 862, p 20) and has been available in Europe since March 1998. However, results of the FocalSeal-L US clinical trial received some criticism (see Clinica No 848, p 13).
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.